Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inferior vena cava interruption. How and when?].

P Girard1

  • 1Département Thoracique, Institut Mutualiste Montsouris, Paris. pgirard@imm.fr

Revue Des Maladies Respiratoires
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serotoninergic Mechanisms of Action in the Relaxant Properties of Saccharomyces boulardii CNCM I-745 on the Intestine.

Digestive diseases and sciences·2024
Same author

Monitoring macroplastics in aquatic and terrestrial ecosystems: Expert survey reveals visual and drone-based census as most effective techniques.

The Science of the total environment·2024
Same author

Stiripentol efficacy against status epilepticus and associated mortality in mice.

Heliyon·2024
Same author

[Translation into French and republication of: "Treatment of cancer-associated venous thromboembolism in patients under palliative care"].

La Revue de medecine interne·2024
Same author

[Translation into French and republication of: "Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management"].

La Revue de medecine interne·2024
Same author

[Translation into French and republication of: "Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment"].

La Revue de medecine interne·2024
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Caval interruption, used for venous thromboembolic disease, has evolving safety data. Current evidence suggests potential risks outweigh benefits in many cases, necessitating further clinical trials.

Area of Science:

  • Vascular Surgery
  • Cardiovascular Medicine
  • Interventional Radiology

Context:

  • Caval interruption, historically the first treatment for venous thromboembolic disease, has evolved through various methods like ligation, plication, clips, and intracaval filters.
  • While modern techniques are considered relatively safe, long-term safety data are scarce, with some studies indicating an increased risk of recurrent deep venous thrombosis with caval filters.

Purpose:

  • To review the historical context, current indications, and evolving safety profile of caval interruption procedures.
  • To evaluate the risk-benefit ratio of caval interruption in various clinical scenarios, particularly in conjunction with anticoagulant therapy and thrombolysis.
  • To highlight the need for further prospective clinical trials to clarify indications and optimize filter selection.

Summary:

Related Experiment Videos

  • Indications for caval interruption are often based on limited evidence, primarily contraindications or failure of anticoagulant treatment for proximal deep venous thrombosis.
  • The PREPIC study demonstrated efficacy in preventing pulmonary embolism, but its addition to anticoagulation in high-risk patients remains debated due to poorly defined 'very high-risk' scenarios.
  • The risk-benefit ratio appears unfavorable when caval interruption is used with thrombolysis or as an alternative to anticoagulation, suggesting a need for more research.

Impact:

  • The findings underscore the need for carefully defined indications and patient selection for caval interruption.
  • Further research is crucial to determine the optimal use of caval filters, especially in high-risk venous thromboembolic disease patients.
  • This review can inform clinical decision-making and guide future research priorities in the management of venous thromboembolic disease.